Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency

Honjo, Kazuhito; Russell, Ronnie M.; Li, Ran; Liu, Weimin; Stoltz, Regina; Tabengwa, Edlue M.; Hua, Yutao; Prichard, Lynn; Kornbrust, Ashton; Sterrett, Sarah; Marques, Marisa B.; Lima, José; Lough, Chris; McCarty, Todd P; Ketas, Thomas J.; Hatziioannou, Théodora; Bieniasz, Paul D.; Redden, David T.; Moore, John P.; Goepfert, Paul; Heath, Sonya L.; Hahn, Beatrice H.; Davis, Randall S.

doi:10.1016/j.xcrm.2020.100164

Cited by 25 publications

(31 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The assay to quantify SARS-CoV-2 S-protein antibodies was modified from one described previously [19]. For serum samples, S-proteins (200 ng in 100 µL) were coated overnight onto 96-well plates at 4ºC.…”

Section: Elisa Proceduresmentioning

confidence: 99%

Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva

Ketas

Chaturbhuj

Portillo

et al. 2021

PAI

Self Cite

112

View full text Add to dashboard Cite

The approved Pfizer and Moderna mRNA vaccines are well known to induce serum antibody responses to the SARS-CoV-2 Spike (S)-protein. However, their abilities to elicit mucosal immune responses have not been reported. Saliva antibodies represent mucosal responses that may be relevant to how mRNA vaccines prevent oral and nasal SARS-CoV-2 transmission. Here, we describe the outcome of a cross-sectional study on a healthcare worker cohort (WELCOME-NYPH), in which we assessed whether IgM, IgG, and IgA antibodies to the S-protein and its receptor-binding domain (RBD) were present in serum and saliva samples. Anti-S-protein IgG was detected in 14/31 and 66/66 of saliva samples from uninfected participants after vaccine doses-1 and -2, respectively. IgA antibodies to the S-protein were present in 40/66 saliva samples after dose 2. Anti-S-protein IgG was present in every serum sample from recipients of 2 vaccine doses. Vaccine-induced antibodies against the RBD were also frequently present in saliva and sera. These findings may help our understanding of whether and how vaccines may impede SARS-CoV-2 transmission, including to oral cavity target cells.

show abstract

Section: Elisa Proceduresmentioning

confidence: 99%

Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva

Ketas

Chaturbhuj

Portillo

et al. 2021

PAI

Self Cite

112

View full text Add to dashboard Cite

show abstract

“…Convalescent plasma (CP) may supplement humoral immunity that is absent in populations most vulnerable to severe disease. 3,4 Effectiveness of therapeutic antibodies and CP to treat or prevent serious disease is dependent on the concentration of functional antibodies and their antigenic specificity and isotype. 5,6 CP can prevent severe disease if it contains sufficiently high antibody titers and is given within 4 days of displaying disease symptoms.…”

Section: Introductionmentioning

confidence: 99%

Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction

et al. 2021

View full text Add to dashboard Cite

Background: Convalescent plasma (CP) therapy for coronavirus disease (COVID-19) provides virus-neutralizing antibodies that may ameliorate the outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The effectiveness of CP likely depends on its antiviral neutralizing potency and is determined using in vitro neutralizing antibody assays.Study design and methods: We evaluated abilities of three immunoassays for anti-spike antibodies (EUROimmun, Ortho, Roche), a pseudotype-based neutralization assay, and two assays that quantify ACE2 binding of spike Abbreviation: SARS-CoV-2, COVID-19, neutralising antibody testing; convalescent plasma. Abigail Lamikanra and Dung Nguyen shared first authors.

show abstract

“…Including the presented case, 19 case reports of prolonged COVID-19 infections occurring in immunocompromised lymphoma patients have been reported and are summarized in Table 1 . 1 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 Median persistence of COVID-19 infections was 65 days (range: 23 days to 12 months), and median time from last lymphoma therapy to COVID-19 onset was 26.5 days (range: during chemotherapy to 8 months). Anti-CD20 antibody therapy was included in most recent lymphoma therapy in 16 out of 19 patients.…”

Section: Discussion and Literature Reviewmentioning

confidence: 99%